Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A loss |
Therapy | Abemaciclib + unspecified PD-1 antibody |
Indication/Tumor Type | melanoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A loss | melanoma | sensitive | Abemaciclib + unspecified PD-1 antibody | Preclinical | Actionable | In a preclinical study, treatment with the combination of Verzenio (abemaciclib) and an anti-PD-1 antibody resulted in inhibition of both intracranial and extracranial tumor growth and improved survival compared to monotherapy or vehicle control in syngeneic mouse models of melanoma with loss of CDKN2A (PMID: 37611074). | 37611074 |
PubMed Id | Reference Title | Details |
---|---|---|
(37611074) | CDK4/6 Inhibition Sensitizes Intracranial Tumors to PD-1 Blockade in Preclinical Models of Brain Metastasis. | Full reference... |